New models of small cell lung cancer to test treatments
SCLC Model Generation and Therapeutic Analysis
Scientists are building new mouse and human cell models of small cell lung cancer to test drug combinations that might work better for patients with this cancer.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11171416 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers will use gene-editing (CRISPR) to create human cell lines and genetically engineered mice that carry the same key mutations found in small cell lung cancer. They will share these standardized cell and animal models across the project so multiple teams can run the same treatment experiments. The team will use imaging and laboratory tests to track how tumors respond and measure drug effects in the models. Results will be used to compare single agents and combinations to guide which approaches move toward clinical testing.
Who could benefit from this research
Good fit: People with a diagnosis of small cell lung cancer, especially those who might enroll in future clinical trials or donate tumor samples, are the most relevant candidates.
Not a fit: Patients without small cell lung cancer or whose tumors lack the specific genetic changes studied here are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could help identify more effective drug combinations and speed the development of treatments for small cell lung cancer.
How similar studies have performed: Preclinical mouse and cell-line models have previously guided lung cancer drug development, but not all promising preclinical findings translate into patient benefit.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Poirier, John Thomas — New York University School of Medicine
- Study coordinator: Poirier, John Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.